Sir Mene Pangalos Outlines AZ's Trio Of COVID-19 Targets
Testing, Developing Antibodies And Repurposing Medicines
The diagnostics tie-up with GSK on testing is a near-term move to help the UK get back to normality, the drug major's biopharmaceuticals R&D boss tells Scrip. AstraZeneca's main focus is to develop monoclonal antibodies to tackle 'wave two' of the coronavirus.
